Dual Role of Lanthanum Oxide Nanoparticles Functionalized Co‐Polymeric Micelle for Extended Anti‐Cancer Drug Delivery

Vinothini, Kandasamy; Jeyaraj, Murugaraj; Kumar, Sadasivuni Kishor; Rajan, Mariappan

doi:10.1002/slct.201803339

Cited by 9 publications

(4 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ZnO could be used as an effective drug carrier for anti-tumor research. The anti-tumor mechanism of lanthanum (La) ions may be attributed to the fact that lanthanum ions open the mitochondrial permeability transition pore, blocking the electron transport chain in the mitochondria, thus increasing the level of reactive oxygen species and inducing cancer cell death ( Anghileri et al, 1987 ; Shuai et al, 2018 ; Vinothini et al, 2019 ).…”

Section: Resultsmentioning

confidence: 99%

Enhancement of fluorescence and anti-tumor effect of ZnO QDs by La doping

et al. 2022

View full text Add to dashboard Cite

ZnO quantum dots (QDs) have received much attention as biomarkers and drug delivery systems in cancer treatment, due to their low cost, ease of preparation, and pH-responsive degradation. However, its applications are limited by the low quantum yield and light absorption. In this work, a lanthanum-doped zinc oxide (La-ZnO) QDs-based drug delivery platform was constructed. The results show that 4% La doping is the most beneficial for improving the fluorescent properties of the ZnO QDs. After loading the drug, the cell activity was 15% at ZnO@DOX and 12% at La-ZnO@DOX. According to in vitro and in vivo experiment results, the La-ZnO QDs show enhancement of the antitumor effect. Dual enhancement of fluorescence and anti-tumor effects make La-ZnO QDs promising as a drug delivery system in cancer treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Enhancement of fluorescence and anti-tumor effect of ZnO QDs by La doping

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Currently, increasingly scientific evidences revealed the evil part of chemotherapy drugs in tumor treatment, including promotions of metastasis, proliferation, immune escape, and so on [ 1 – 3 ]. Therefore, to develop new treatment strategies for cancer based on biomarkers has been under continuous investigation during the past a few year [ 4 – 14 ]. One of the most highlighted progresses is the successful achievement of chimeric antigen receptor (CAR) T cells in B cell lymphoma [ 10 – 13 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Vγ9Vδ2 T cells strengthen cisplatin inhibition activity against breast cancer MDA-MB-231 cells by disrupting mitochondrial function and cell ultrastructure

Huang

Wang

2021

Cancer Cell Int

View full text Add to dashboard Cite

Background Breast cancer ranks second of new cases and fifth of death in 2018 worldwide. Cis-platinum (CDDP) has been used as a chemotherapy to treat breast cancer for years. However, CDDP can adversely disrupt immune function of host. Thus, development of new protocol that can minimize side effect and meanwhile elevate clinical efficacy of CDDP will eventually benefit cancer patients. Since Vγ9Vδ2 T cells can up-regulate immune function of cancer patients, therefore, our hypothesis is that introduction of Vγ9Vδ2 T cells could potentiate CDDP efficacy against breast cancer. Methods We used breast cancer cell line MDA-MB-231 as model cell to test our hypothesis. The cancer cell viability in vitro in the context of different dose of CDDP was analyzed by flow cytometry. The cytoskeleton alteration was visualized by confocal microscopy, and the ultrastructure of cell membrane was observed by atomic force microscopy. The mitochondrial function of MDA-MB-231 cells was detected as well by flow cytometry. Results Comparing to either Vγ9Vδ2 T cells or CDDP alone, Vγ9Vδ2 T cells plus CDDP could more strikingly induce MDA-MB-231 cell membrane ultrastructure disruption and cytoskeleton disorder, and more significantly enhance the inhibition of CDDP on proliferation of MDA-MB-231 cells. At the same time, Vγ9Vδ2 T cells strengthened CDDP-induced mitochondrial dysfunction of cancer cells. Conclusion This work revealed that Vγ9Vδ2 T cells could synergistically enhance the inhibition activity of CDDP against breast cancer cells. Meanwhile, this in vitro proof-of-concept study implied the clinical prospect of the combining application of Vγ9Vδ2 T cells and CDDP in breast cancer therapy.

show abstract

“…Currently, increasingly scientific evidences revealed the evil part of chemotherapy drugs in tumor treatment, including promotions of metastasis, proliferation, immune escape, and so on [1][2][3]. Therefore, to develop new treatment strategies [4][5][6][7][8][9][10][11][12][13] for cancer has been under continuous investigation during the past a few years. One of the most highlighted progresses is the successful achievement of chimeric antigen receptor (CAR) T cells in B cell lymphoma [10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Vγ9Vδ2 T cells strengthen cisplatin inhibition activity against breast cancer MDA-MB-231 cells by disrupting mitochondrial function and cell ultrastructure

Huang

Wang

2021

Preprint

View full text Add to dashboard Cite

Background: Breast cancer ranks second of new cases and fifth of death in 2018 worldwide. Cis-platinum (CDDP) has been used as a chemotherapy to treat breast cancer for years. However, CDDP can adversely disrupt immune function of host. Thus, development of new protocol that can minimize side effect and meanwhile elevate clinical efficacy of CDDP will eventually benefit cancer patients. Since Vg9Vd2 T cells can up-regulate immune function of cancer patients, therefore, our hypothesis is that introduction of Vg9Vd2 T cells could potentiate CDDP efficacy against breast cancer.Methods: We used breast cancer cell line MDA-MB-231 as model cell to test our hypothesis. The cancer cell viability in vitro in the context of different dose of CDDP was analyzed by flow cytometry. The cytoskeleton alteration was visualized by confocal microscopy, and the ultrastructure of cell membrane was observed by atomic force microscopy. The mitochondrial function of MDA-MB-231 cells was detected as well by flow cytometry.Results: Comparing to either Vγ9Vδ2 T cells or CDDP alone, Vg9Vd2 T cells plus CDDP could more strikingly induce MDA-MB-231 cell membrane ultrastructure disruption and cytoskeleton disorder, and more significantly enhance the inhibition of CDDP on proliferation of MDA-MB-231 cells. At the same time, Vγ9Vδ2 T cells strengthened CDDP-induced mitochondrial dysfunction of cancer cells.Conclusion: This work revealed that Vγ9Vδ2 T cells could synergistically enhance the inhibition activity of CDDP against breast cancer cells. Meanwhile, this in vitro proof-of-concept study implied the clinical prospect of the combining application of Vγ9Vδ2 T cells and CDDP in breast cancer therapy.

show abstract

Dual Role of Lanthanum Oxide Nanoparticles Functionalized Co‐Polymeric Micelle for Extended Anti‐Cancer Drug Delivery

Cited by 9 publications

References 48 publications

Enhancement of fluorescence and anti-tumor effect of ZnO QDs by La doping

Enhancement of fluorescence and anti-tumor effect of ZnO QDs by La doping

Vγ9Vδ2 T cells strengthen cisplatin inhibition activity against breast cancer MDA-MB-231 cells by disrupting mitochondrial function and cell ultrastructure

Vγ9Vδ2 T cells strengthen cisplatin inhibition activity against breast cancer MDA-MB-231 cells by disrupting mitochondrial function and cell ultrastructure

Contact Info

Product

Resources

About